Showing 1381-1390 of 1717 results for "".
- American Heart Association Presidential Advisory Adds Sleep as Key Metric for Cardiovascular Healthhttps://practicalneurology.com/news/american-heart-association-presidential-advisory-adds-sleep-as-key-metric-for-cardiovascular-health/2469957/In a new Presidential Advisory from the American Heart Association (AHA), sleep duration has been added as an essential component for ideal heart and brain health. The update to this advisory was prepared by a volunteer wr
- GAIN Study Tests Gum Disease-Associated Protein as Target for Disease-Modifying Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/gain-study-tests-gum-disease-associated-protein-as-target-for-disease-modifying-treatment-of-alzheimer-disease/2469650/Characteristics of the study design and population for the ongoing phase 2/3 GAIN trial (NCT03823404) of atuzaginstat (COR338; Cortexyme, South San Francisco, CA) were presented at the Alzheimer Association International Conference Jul
- Interim Data from KINECT-HD2 Study Indicates Ingrezza Treatment Leads to Sustained Long-Term Improvements in Chorea Symptoms Associated with Huntingdon Diseasehttps://practicalneurology.com/news/interim-data-from-kinect-hd2-study-indicates-ingrezza-treatment-leads-to-sustained-long-term-improvements-in-chorea-symptoms-associated-with-huntingdon-disease/2470335/Researchers reported that Ingrezza treatment was associated with long-term improvements through 50 weeks in patients with chorea symptoms associated with Huntington disease (HD). Results from this analysis of interim data from the KINECT-HD2 (NCT04400331) open-label extension (OLE) study were pre
- Extended-Release Ciprofloxacin + Celecoxib Associated with Prolonged Survival in Phase 2b ALS Trial Extensionhttps://practicalneurology.com/news/extended-release-ciprofloxacin-celecoxib-associated-with-prolonged-survival-in-phase-2b-als-trial-extension/2485801/Treatment with PrimeC (ciprofloxacin and celecoxib extended release; NeuroSense Therapeutics, Cambridge, MA) was associated with prolonged overall survival in people with amyotrophic lateral sclerosis (ALS), according to results from extended follow-up from the PARADIGM phase 2b clinical trial (N
- GLP-1RAs and SGLT2is Associated with Lower Dementia Risk in People with Type 2 Diabeteshttps://practicalneurology.com/news/glp-1ras-and-sglt2is-associated-with-lower-dementia-risk-in-people-with-type-2-diabetes/2474356/Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a significantly reduced risk of developing Alzheimer disease and related dementias (ADRD) in individuals people diagnosed with type 2 diabetes mellitus (
- Research Presented at ANA 2024 Reveals Association Between Paramagnetic Rim Lesions and Disability/Disease Progression in People with MShttps://practicalneurology.com/news/research-presented-at-ana-2024-reveals-association-between-paramagnetic-rim-lesions-and-disabilitydisease-progression-in-people-with-ms/2470577/For people with multiple sclerosis (MS), a higher number of persisting paramagnetic rim lesions (PRLs) was associated with increased odds of progression independent of relapse activity (PIRA) and confirmed disability progression (CDP), according to data presented at the 2024 annual meeting of the
- Muscular Dystrophy Association Launches Initiative to Support the Development of Treatments for Ultra-Rare Neuromuscular Diseaseshttps://practicalneurology.com/news/muscular-dystrophy-association-launches-initiative-to-support-the-development-of-treatments-for-ultra-rare-neuromuscular-diseases/2470571/The Muscular Dystrophy Association (MDA) announced the launch of the MDA Kickstart Program, an initiative to advance the development of treatments for ultra-rare neuromuscular diseases. The first project under the MDA Kickstart Program will focus on the development of a gene therapy for a rare fo
- Leqembi Treatment Associated with Sustained Reduction in Cognitive Decline According to 3-Year OLE Resultshttps://practicalneurology.com/news/leqembi-treatment-associated-with-sustained-reduction-in-cognitive-decline-according-to-3-year-ole-results/2470545/New 3-year open-label extension (OLE) results from the Clarity AD clinical trial (NCT03887455) presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) showed sustained reductions in cognitive decline in participants with early Alzheimer disease (AD) trea
- FDA Approves Once-Daily Austedo XR for Tardive Dyskinesia and Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-once-daily-austedo-xr-for-tardive-dyskinesia-and-chorea-associated-with-huntington-disease/2470487/The Food and Drug Administration (FDA) has approved Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) extended-release tablets, a new once-daily formulation of Austedo for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) in adults. Austed
- Significant Association Between COVID-19 Infection and Cerebral Microbleeds Found in New Studyhttps://practicalneurology.com/news/significant-association-between-covid-19-infection-and-cerebral-microbleeds-found-in-new-study/2470465/According to study results published in Brain Communications, COVID-19 infection was associated with a significantly greater likelihood of cerebral microbleeds (CMBs) on medically indicated brain MRI. Incidental findings of CMBs have been discovered on brain MRI in COVID-19 cohorts